Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease

Trial Profile

Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2016

At a glance

  • Drugs Sitagliptin (Primary)
  • Indications Non-alcoholic fatty liver disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 May 2016 Primary endpoint of improving hepatic steatosis assessed by magnetic resonance imaging has not been met, according to results published in the Journal of Hepatology.
    • 02 May 2016 Status changed from active, no longer recruiting to completed according to results published in the Journal of Hepatology.
    • 02 May 2016 Results published in the Journal of Hepatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top